InsidersTradesSigma
Track the 新华制药 stock price and the full management transaction log of the company, a listed equity based in China. Shares are quoted on the CN market, under the authority of SSE / SZSE (CSRC). Operating in the Health Care sector, 新华制药 has published 4 insider filings. Market capitalisation: €9.4bn. The latest transaction was filed on 29 July 2022 (Sale). Among the most active insiders: 王小龙. Every trade is openly available.
4
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
€255,367
4 ops.
Sell Volume
22Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 15,936 of 28,697 companies
48.9
score / 100
Value56
Quality42
FCF yld4.4%
Earn yld3.1%
EV/EBITDA11.0x
ROE5.0%
Gross mgn19%
Net mgn3.3%
Debt/EBITDA1.5x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 29 July 2022
About 新华制药
新华制药 is a pharmaceutical company based in China that specializes in the manufacturing of pharmaceutical products. It focuses on the development and production of generic drugs and innovative medications.